In non-small cell lung cancer (NSCLC) or glioblastoma where EGFR driver mutation (EGFR-mut) and/or gene amplification are prevalent, mTOR activation contributes to disease progression, metastasis and tyrosine kinase inhibitor (TKI) resistance (3–6). This evidence concerns the gene EGFR and non-small cell lung carcinoma.